Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (155) 155
Book / eBook (143) 143
Newspaper Article (35) 35
Publication (14) 14
Dissertation (11) 11
Magazine Article (9) 9
Book Chapter (6) 6
Reference (5) 5
Streaming Audio (4) 4
Book Review (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (56) 56
united states (47) 47
female (46) 46
middle aged (44) 44
index medicus (42) 42
aged (41) 41
oncology (40) 40
adult (39) 39
history (37) 37
male (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
aged, 80 and over (22) 22
treatment outcome (18) 18
chemotherapy (17) 17
research (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
cancer (15) 15
disease-free survival (14) 14
breast cancer (13) 13
breast neoplasms - drug therapy (12) 12
care and treatment (12) 12
bibliography (11) 11
biography (11) 11
correspondence (11) 11
analysis (10) 10
breast neoplasms - pathology (10) 10
clinical trials (10) 10
lung neoplasms - drug therapy (10) 10
animals (9) 9
geschichte (9) 9
health aspects (9) 9
metastasis (9) 9
survival (9) 9
trial (9) 9
united states history (9) 9
20th century (8) 8
antibodies, monoclonal - administration & dosage (8) 8
antibodies, monoclonal - adverse effects (8) 8
aufsatzsammlung (8) 8
bevacizumab (8) 8
electronic books (8) 8
histoire (8) 8
kaplan-meier estimate (8) 8
management (8) 8
neoplasm metastasis (8) 8
neoplasm staging (8) 8
postmenopausal women (8) 8
toxicity (8) 8
american literature (7) 7
american poetry (7) 7
carcinoma, non-small-cell lung - drug therapy (7) 7
colorectal neoplasms - drug therapy (7) 7
combination (7) 7
criticism and interpretation (7) 7
description and travel (7) 7
drug therapy (7) 7
endocrine therapy (7) 7
english literature (7) 7
history and criticism (7) 7
medicine & public health (7) 7
poetry (7) 7
politics and government (7) 7
social conditions (7) 7
survival rate (7) 7
women (7) 7
antimitotic agents (6) 6
antineoplastic agents (6) 6
article (6) 6
authors, american (6) 6
cancer therapies (6) 6
colorectal neoplasms - pathology (6) 6
drug administration schedule (6) 6
education (6) 6
expression (6) 6
hematology, oncology and palliative medicine (6) 6
old state library collection (6) 6
patients (6) 6
studies (6) 6
study and teaching (6) 6
tumors (6) 6
usa (6) 6
antibodies, monoclonal, humanized (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
authors (5) 5
bibliographies (5) 5
biographies (5) 5
books (5) 5
camptothecin - analogs & derivatives (5) 5
clinical trial (5) 5
dictionaries (5) 5
docetaxel (5) 5
fluorouracil - administration & dosage (5) 5
irinotecan (5) 5
literature (5) 5
lung neoplasms - pathology (5) 5
medicine, general & internal (5) 5
mice (5) 5
monoclonal antibodies (5) 5
oncology, experimental (5) 5
paclitaxel (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (61) 61
UTL at Downsview - May be requested (47) 47
Online Resources - Online (15) 15
St. Michael's College (John M. Kelly) - 2nd Floor (14) 14
UofT at Mississauga - Stacks (14) 14
Victoria University E.J. Pratt - Stacks (13) 13
Thomas Fisher Rare Book - Rare Book (12) 12
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
UofT at Scarborough - Stacks (8) 8
Trinity College (John W Graham) - Stacks (7) 7
Gerstein Science - Stacks (6) 6
Massey College (Robertson Davies) - Rare Book (6) 6
Law (Bora Laskin) - Stacks (5) 5
OISE - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Trinity College (John W Graham) - Storage (3) 3
Victoria University Emmanuel College - Stacks (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
St. Michael's College (John M. Kelly) - 3rd Floor (2) 2
University College (Laidlaw) - May be requested in 6-10 wks (2) 2
Victoria University E.J. Pratt - Storage (2) 2
Architecture Landscape (Shore + Moffat) - Stacks (1) 1
Art - Library use only (1) 1
Astronomy & Astrophysics - Ask at library (1) 1
Business (Joseph L Rotman) - Library use only (1) 1
Faculty of Information - May be requested in 6-10 wks (1) 1
Institute for Christian Studies - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Music - Stacks (1) 1
New College (Ivey) - Oversize (1) 1
New College (Ivey) - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Regis College - Stacks (1) 1
Royal Ontario Museum - Periodical Stacks (1) 1
St. Augustine's Seminary - Reference (1) 1
St. Augustine's Seminary - Stacks (1) 1
Thomas Fisher Rare Book - Reference (1) 1
United Church of Canada Archives - Archives (1) 1
University College (Laidlaw) - Purdy (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Mississauga - Reference (1) 1
Victoria University E.J. Pratt - Circulation Desk (1) 1
Victoria University Emmanuel College - Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
by Eng, Cathy and Bessudo, Alberto and Hart, Lowell L and Severtsev, Aleksey and Gladkov, Oleg and Müller, Lothar and Kopp, Mikhail V and Vladimirov, Vladimir and Langdon, Robert and Kotiv, Bogdan and Barni, Sandro and Hsu, Ching and Bolotin, Ellen and von Roemeling, Reinhard and Schwartz, Brian and Bendell, Johanna C
International Journal of Cancer, ISSN 0020-7136, 07/2016, Volume 139, Issue 1, pp. 177 - 186
Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type (KRAS WT), metastatic colorectal cancer... 
metastatic colorectal cancer | irinotecan | KRAS wild‐type | tivantinib | MET inhibitor | KRAS wild-type | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Quinolines - administration & dosage | Pyrrolidinones - administration & dosage | Disease-Free Survival | Irinotecan | Neoplasm Metastasis | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Colorectal Neoplasms - pathology | Camptothecin - analogs & derivatives | Immunohistochemistry | Antimitotic agents | Medical research | Cancer patients | Care and treatment | Chemotherapy | Analysis | Colorectal cancer | Medicine, Experimental | Metastasis | Antineoplastic agents | Cancer | Studies | Confidence intervals | Drug dosages | Cancer therapies | Tumors | Cancer Therapy and Prevention
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results
by Bardia, Aditya and Hurvitz, Sara A and DeMichele, Angela and Clark, Amy Sanders and Zelnak, Amelia Bruce and Yardley, Denise A and Karuturi, Meghan Sri and Sanft, Tara B and Blau, Sibel and Hart, Lowell L and Ma, Cynthia X and Caria, Nicola and Purkayastha, D. Das and Mistry, Alomi and Moulder, Stacy L
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 1016 - 1016
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2
by Burris, Howard A and Tolaney, Sara M and Hart, Lowell L and Favret, Anne and Alemany, Carlos A and Volas-Redd, Gena H and Shtivelband, Mikhail and Chandiwana, David and Purkayastha, D. Das and Caria, Nicola and Baeck, Johan and Hortobagyi, Gabriel N
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 1041 - 1041
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets)
by Yardley, Denise A and Hainsworth, John D and Hamilton, Erika Paige and Hart, Lowell L and Shastry, Mythili and DeBusk, Laura M and Burris, Howard A
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. TPS667 - TPS667
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study
by Yardley, Denise A and Hart, Lowell L and Ward, Patrick J and Wright, Gail L and Shastry, Mythili and Finney, Lindsey and DeBusk, Laura M and Hainsworth, John D
Clinical Breast Cancer, ISSN 1526-8209, 10/2018, Volume 18, Issue 5, pp. e781 - e787
The present phase II study evaluated lapatinib plus cabazitaxel in HER2 metastatic breast cancer patients with brain metastases. Patients were treated at 2... 
CNS metastases | Human epidermal growth factor receptor 2-positive breast cancer | Brain metastases | Phase II | MBC | SURVIVAL | SUBTYPES | MULTICENTER PHASE-II | BLOOD-BRAIN-BARRIER | PACLITAXEL | CAPECITABINE | TRIAL | WOMEN | NERVOUS-SYSTEM METASTASES | ONCOLOGY | TAXANE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
by Hortobagyi, Gabriel N and Stemmer, Salomon M and Burris, Howard A and Yap, Yoon-Sim and Sonke, Gabe S and Paluch-Shimon, Shani and Campone, Mario and Blackwell, Kimberly L and André, Fabrice and Winer, Eric P and Janni, Wolfgang and Verma, Sunil and Conte, Pierfranco and Arteaga, Carlos L and Cameron, David A and Petrakova, Katarina and Hart, Lowell L and Villanueva, Cristian and Chan, Arlene and Jakobsen, Erik and Nusch, Arnd and Burdaeva, Olga and Grischke, Eva-Maria and Alba, Emilio and Wist, Erik and Marschner, Norbert and Favret, Anne M and Yardley, Denise and Bachelot, Thomas and Tseng, Ling-Ming and Blau, Sibel and Xuan, Fengjuan and Souami, Farida and Miller, Michelle and Germa, Caroline and Hirawat, Samit and O’Shaughnessy, Joyce
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
In patients with advanced HR-positive, HER2-negative breast cancer, the addition of the cyclin-dependent kinase inhibitor ribociclib to letrozole was... 
CRITERIA | CONTROLLED-TRIAL | PALBOCICLIB | MEDICINE, GENERAL & INTERNAL | PLACEBO | CDK4/6 | CLINICAL-TRIALS | DOUBLE-BLIND | ESTROGEN | POSTMENOPAUSAL WOMEN | Aminopyridines - administration & dosage | Triazoles - administration & dosage | Double-Blind Method | Drug Administration Schedule | Receptors, Estrogen | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Purines - administration & dosage | Breast Neoplasms - drug therapy | Nitriles - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Receptors, Progesterone | Aged, 80 and over | Adult | Female | Aged | Receptor, ErbB-2 | Neoplasm Staging | Letrozole | Care and treatment | Postmenopausal women | Breast cancer | Health aspects | Leukopenia | Estrogen | Endocrine therapy | Metastasis | Kinases | Cancer therapies | Survival | Patients | ErbB-2 protein | Cyclin-dependent kinase 4 | Post-menopause | Metastases | Proteins | Epidermal growth factor | Womens health | Myelosuppression | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cabazitaxel Plus Lapatinib as Therapy for HER2.sup.+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study
by Yardley, Denise A and Hart, Lowell L and Ward, Patrick J and Wright, Gail L and Shastry, Mythili and Finney, Lindsey and DeBusk, Laura M and Hainsworth, John D
Clinical Breast Cancer, ISSN 1526-8209, 10/2018, Volume 18, Issue 5, p. e781
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.clbc.2018.03.004 
Breast cancer | Metastasis | Research | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types
by Jhaveri, Komal L and Bedard, Philippe L and Cejalvo, Juan Miguel and Hart, Lowell L and Juric, Dejan and Kelly, Karen and Lockhart, A. Craig and Melnyk, Anton and Moore, Kathleen N and Nemunaitis, John J and Oliveira, Mafalda and Patel, Manish R and Sachdev, Jasgit and Smith, David and VanderWalde, Ari and Ware, Joseph A and Jin, Huan and Wilson, Timothy R and Wei, Michael C and Baselga, Jose
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS11621 - TPS11621
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors
by Mahalingam, Devalingam and Patel, Manish R and Sachdev, Jasgit C and Hart, Lowell L and Halama, Niels and Ramanathan, Ramesh K and Sarantopoulos, John and Liu, Xiaochun and Yazji, Salim and Jaeger, Dirk and Adib, Deyaa and Kerschbaumer, Randolf and Tsimberidou, Apostolia Maria
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. CT046 - CT046
Background: MIF is a pleiotropic cytokine involved in tumor proliferation, invasiveness, angiogenesis, and the proinflammatory microenvironment. oxMIF is the... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings
by Bauer, Todd M and Jones, Suzanne F and Greenlees, Carol and Cook, Carl and Mugundu, Ganesh M and Jewsbury, Philip J and Pierce, Andrew J and O’Connor, Mark J and Johnson, Melissa L and Beck, J. Thaddeus and Moore, Kathleen N and Hart, Lowell L and Infante, Jeffery R and Burris, Howard A and Spigel, David
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. CT013 - CT013
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study
by Summa, Jason M and Von Hoff, Daniel D and Sachdev, Jasgit C and Mita, Monica M and LoRusso, Patricia M and Eisenberg, Peter D and Burris, Howard A and Hart, Lowell L and Youssoufian, Hagop and Parsons, Donald M and Low, Susan C
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. B144 - B144
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy
: Phase 1/2 Study of Tivantinib in Combination with Irinotecan and Cetuximab
by Eng, Cathy and Bessudo, Alberto and Hart, Lowell L and Severtsev, Aleksey and Gladkov, Oleg and Müller, Lothar and Kopp, Mikhail V and Vladimirov, Vladimir and Langdon, Robert and Kotiv, Bogdan and Barni, Sandro and Hsu, Ching and Bolotin, Ellen and von Roemeling, Reinhard and Schwartz, Brian and Bendell, Johanna C
International Journal of Cancer, ISSN 0020-7136, 07/2016, Volume 139, Issue 1, pp. 177 - 186
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors
by Mahalingam, Devalingam and Patel, Manish R and Sachdev, Jasgit C and Hart, Lowell L and Halama, Neils and Ramanathan, Ramesh K and Sarantopoulos, John and Liu, Xiaochun and Yazji, Salim and Jaeger, Dirk and Adib, Deyaa Rafaat and Kerschbaumer, Randolf and Tsimberidou, Apostolia Maria
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 2518 - 2518
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts
by Berdeja, Jesus G and Gregory, Tara B and Faber, Edward A and Matous, Jeffrey V and Hart, Lowell L and Mace, Joseph R and Peyton, James D and Essell, James H and Arrowsmith, Edward R and Flinn, Ian W
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1825 - 1825
Abstract Background: Proteasome inhibitors (PI) such as bortezomib (BTZ) and carfilzomib (CFZ) have improved the treatment (tx) of MM; however, resistance... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
by Chiang, Anne C and Rudin, Charles M and Spira, Alexander I and Jotte, Robert M and Gadgeel, Shirish M and Mita, Alain C and Hart, Lowell L and Gluck, William Larry and Liu, Stephen V and Kapoun, Ann M and Xu, Lu and Hill, Dawn and Zhou, Lei and Dupont, Jakob and Spigel, David R
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 8564 - 8564
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
by Howard S. Hochster and Lowell L. Hart and Ramesh K. Ramanathan and Barrett H. Childs and John D. Hainsworth and Allen L. Cohn and Lucas Wong and Louis Fehrenbacher and Yousif Abubakr and M. Wasif Saif and Lee Schwartzberg and Eric Hedrick
Journal of Clinical Oncology, ISSN 0732-183X, 07/2008, Volume 26, Issue 21, pp. 3523 - 3529
Purpose To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for... 
RANDOMIZED-TRIAL | PHASE-II | IRINOTECAN | LEUCOVORIN | ONCOLOGY | FLUOROURACIL | Leucovorin - administration & dosage | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes
by Hahn, Noah M and Picus, Joel and Bambury, Richard Martin and Pal, Sumanta Kumar and Hart, Lowell L and Grivas, Petros and Milowsky, Matthew I and Alva, Ajjai Shivaram and Sonpavde, Guru and Mortazavi, Amir and Bellmunt, Joaquim and Guancial, Elizabeth A and Gupta, Sumati and Chao, Richard C and Collier, Mary A and Christensen, James and Chen, Isan and Rosenberg, Jonathan E
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. TPS4575 - TPS4575
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM)
by Berdeja, Jesus G and Gregory, Tara K and Matous, Jeffrey and Hart, Lowell L and Owera, Rami and Mace, Joseph Ronald and Essell, James H and Flinn, Ian and Faber, Edward Anthony
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 8513 - 8513
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
by Pietanza, Maria Catherine and Spira, Alexander I and Jotte, Robert M and Gadgeel, Shirish M and Mita, Alain C and Hart, Lowell L and Gluck, W Larry and Chiang, Anne C and Liu, Stephen V and Kapoun, Ann M and Xu, Lu and Hill, Dawn and Dupont, Jakob and Spigel, David R and Zhou, Lei
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 7508 - 7508
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
by Shirin Khambata-Ford and Christopher T. Harbison and Lowell L. Hart and Melissa Awad and Li-An Xu and Christine E. Horak and Shaker Dakhil and Robert C. Hermann and Thomas J. Lynch and Martin R. Weber
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 6, pp. 918 - 927
Purpose The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive... 
KRAS MUTATIONS | K-RAS MUTATIONS | GEFITINIB | GROWTH-FACTOR-RECEPTOR | PLUS CETUXIMAB | ONCOLOGY | BRONCHIOLOALVEOLAR-CARCINOMA | GENE COPY NUMBER | EXPRESSION | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antibodies, Monoclonal, Humanized | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Survival Rate | Treatment Outcome | Gene Dosage | Mutation - genetics | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.